We are live on ! Find out more
JNCE

Jounce Therapeutics, Inc. Common Stock
JNCE

Delisted

JNCE was delisted on the 3rd of May, 2023.

Back to rankings

90 hedge funds and large institutions have $180M invested in Jounce Therapeutics, Inc. Common Stock in 2020 Q2 according to their latest regulatory filings, with 13 funds opening new positions, 29 increasing their positions, 32 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

399% more call options, than puts

Call options by funds: $639K | Put options by funds: $128K

43% more capital invested

Capital invested by funds: $125M → $180M (+$54.3M)

18% more first-time investments, than exits

New positions opened: 13 | Existing positions closed: 11

2% more funds holding

Funds holding: 88 → 90 (+2)

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

9% less repeat investments, than reductions

Existing positions increased: 29 | Existing positions reduced: 32

Holders
90
Holders Change
+2
Holders Change %
+2.27%
% of All Funds
1.85%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.04%
New
13
Increased
29
Reduced
32
Closed
11
Calls
$639K
Puts
$128K
Net Calls
+$511K
Net Calls Change
+$279K

Top Buyers

Rank Fund Capital Flow
1
Citadel Advisors
Citadel Advisors
Florida
+$2.22M
2
GIM
Granahan Investment Management
Massachusetts
+$1.36M
3
Invesco
Invesco
Georgia
+$1.24M
4
Northern Trust
Northern Trust
Illinois
+$684K
5
Dimensional Fund Advisors
Dimensional Fund Advisors
Texas
+$384K

Top Sellers

Rank Fund Capital Flow
1
BCM
Bridgeway Capital Management
Texas
-$1.59M
2
Renaissance Technologies
Renaissance Technologies
New York
-$1.1M
3
Marshall Wace
Marshall Wace
United Kingdom
-$927K
4
AQR Capital Management
AQR Capital Management
Connecticut
-$906K
5
Verition Fund Management
Verition Fund Management
Connecticut
-$696K
Name Holding Trade Value Shares
Change 		Change in
Stake
SEI Investments
26
SEI Investments
Pennsylvania
$949K +$168K +31,080 +29%
JP Morgan Chase
27
JP Morgan Chase
New York
$935K -$82.8K -15,341 -10%
Bank of Montreal
28
Bank of Montreal
Ontario, Canada
$753K +$33.4K +6,199 +6%
QI
29
QS Investors
New York
$697K – – –
CAM
30
Congress Asset Management
Massachusetts
$646K +$6.26K +1,160 +1%
Los Angeles Capital Management
31
Los Angeles Capital Management
California
$638K +$213K +39,494 +75%
Marshall Wace
32
Marshall Wace
United Kingdom
$582K -$927K -171,770 -67%
Wells Fargo
33
Wells Fargo
California
$576K +$50.8K +9,409 +13%
Axa
34
Axa
France
$508K – – –
EIM
35
Essex Investment Management
Massachusetts
$501K -$192K -35,597 -33%
SO
36
STRS Ohio
Ohio
$490K -$186K -34,500 -33%
N
37
Nuveen
North Carolina
$483K +$10.6K +1,963 +3%
Goldman Sachs
38
Goldman Sachs
New York
$392K -$125K -23,090 -29%
AllianceBernstein
39
AllianceBernstein
Tennessee
$390K +$34K +6,300 +13%
New York State Common Retirement Fund
40
New York State Common Retirement Fund
New York
$342K +$82.4K +15,278 +44%
Prudential Financial
41
Prudential Financial
New Jersey
$312K -$136K -25,293 -36%
First Manhattan
42
First Manhattan
New York
$303K – – –
LPL Financial
43
LPL Financial
California
$298K +$2.51K +465 +1%
YMRC
44
Yorktown Management & Research Company
Virginia
$297K +$232K +43,000 New
Federated Hermes
45
Federated Hermes
Pennsylvania
$278K -$50.1K -9,284 -19%
SFM
46
Systematic Financial Management
New Jersey
$250K -$108K -19,990 -36%
PPA
47
Parametric Portfolio Associates
Washington
$224K +$83.6K +15,497 +91%
BCM
48
Bridgeway Capital Management
Texas
$216K -$1.59M -294,200 -90%
RhumbLine Advisers
49
RhumbLine Advisers
Massachusetts
$201K +$7.2K +1,334 +5%
AG
50
Algert Global
California
$187K -$71.8K -13,320 -33%
1
2
3 4

JNCE Hedge Fund Activity: Q2 2020 in Review

90 of the 4,877 institutional investors tracked by Wall St. Rank reported a position in Jounce Therapeutics, Inc. Common Stock (JNCE) for Q2 2020, worth a combined $180M — up 43% from $125M a quarter earlier.

Buyers outnumbered sellers: 13 funds opened new JNCE positions and 11 closed out — a net gain of 2 holders — while 29 added to existing stakes and 32 trimmed.

The largest buyer was Citadel Advisors, adding an estimated $2.22M. The largest seller was Bridgeway Capital Management, cutting an estimated $1.59M.

  • 90 institutional investors held Jounce Therapeutics, Inc. Common Stock (JNCE) as of Q2 2020, up from 88 in Q1 2020.
  • Funds reported $180M of Jounce Therapeutics, Inc. Common Stock stock for Q2 2020, up 43% quarter-over-quarter.
  • 13 funds opened new Jounce Therapeutics, Inc. Common Stock positions in Q2 2020 and 11 closed out, a net change of +2 holders.
  • The largest Jounce Therapeutics, Inc. Common Stock buyer in Q2 2020 was Citadel Advisors, an estimated $2.22M added.
  • The largest Jounce Therapeutics, Inc. Common Stock seller in Q2 2020 was Bridgeway Capital Management, an estimated $1.59M sold.

Based on aggregated 13F filings for Q2 2020.